Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation

Hiroyuki Kanazawa, Akinari Fukuda, Vidyadhar Padmakar Mali, Tri Hening Rahayatri, Yoshihiro Hirata, Kengo Sasaki, Hajime Uchida, Takanobu Shigeta, Seisuke Sakamoto, Kimikazu Matsumoto, Mureo Kasahara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

LT from ABO-I donors requires preconditioning regimens to prevent postoperative catastrophic AMR. NAC for HBL is known to cause myelosuppression leading to a reduction in the number and function of lymphocytes. We investigated this chemotherapy-induced myelosuppression in HBL patients listed for LT from ABO-I donors with reference to the kinetics of B, T cells, and anti-ABO blood type isoagglutinin titers. Between 2005 and 2015, of the 319 patients who underwent LDLT at our institute, 12 were indicated for unresectable HBL. Three patients with unresectable HBL who underwent LDLT from ABO-I donors are included in this study. Immunosuppression consisted of a standard regime of tacrolimus and low-dose steroids as in ABO compatible/identical LDLT. No additional preoperative therapies for B-cell depletion were used. Absolute lymphocyte counts, lymphocyte subsets (including CD20+ B cells, CD3+CD4+ T cells and CD3+CD8+ T cells), and anti-ABO blood type isoagglutinin titers were measured before LDLT and postoperatively. The median age at diagnosis was 19 months (range, 3-31 months). The median follow-up was seven months (range, 6-15 months). The median interval from the last NAC to LDLT was 33 days (range, 25-52 days). The median interval from LDLT to adjuvant chemotherapy was 28 days (range, 22-36 days). The counts of CD20+ B cells before LDLT were depleted to median 5 cells/mm3 (range, 0-6 cells/mm3). There was a transient rebound in the CD20+ B cell counts on day seven (maximum of 82 cells/mm3) followed by a decline starting at 14 days after LDLT that was sustained for the duration of adjuvant chemotherapy. Anti-ABO blood type isoagglutinin titers were lowered to between 1:1 and 1:16 before LDLT and remained low for the duration of follow-up in this study. All of the three patients remained in good health without either acute cellular or AMR after LDLT. The B-cell depletion that occurs after cisplatin-based chemotherapy for HBL may help accomplish safe ABO-I LDLT in children without the use of additional conditioning regimens for prevention of AMR.

Original languageEnglish
Pages (from-to)401-407
Number of pages7
JournalPediatric Transplantation
Volume20
Issue number3
DOIs
Publication statusPublished - 1 May 2016

Keywords

  • ABO blood type incompatible
  • chemotherapy
  • hepatoblastoma
  • living donor liver transplantation
  • SIOPEL

Fingerprint Dive into the research topics of 'Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation'. Together they form a unique fingerprint.

  • Cite this

    Kanazawa, H., Fukuda, A., Mali, V. P., Rahayatri, T. H., Hirata, Y., Sasaki, K., Uchida, H., Shigeta, T., Sakamoto, S., Matsumoto, K., & Kasahara, M. (2016). Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation. Pediatric Transplantation, 20(3), 401-407. https://doi.org/10.1111/petr.12675